Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
29 results
D2.426 - Polarization of PBMCs during SARS-CoV-2 Infections
D2.432 - Therapeutic Efficacy of Platelet-Rich Plasma in Androgenic Alopecia: A Meta-Analysis of Single Versus Double-Blinded Randomized Controlled Trials
D2.423 - Changes in the expression of regulatory receptors on CD8+ T cytotoxic lymphocytes as a marker of the risk of developing a post COVID-19 condition in patients after a severe course of COVID-19
D2.425 - Type 2 neuro-immune signaling is upregulated in Candida albicans-driven itch
D2.427 - Inhibition of the IL-17 pathway in the treatment of systemic vasculitis: molecular biology and case review
D2.428 - Contribution of Allelic Gene Variants of the Indoleamine-2,3-Dioxygenase and Dectin-1 to the Risk of Invasive Aspergillosis in Oncohematological Patients
D2.429 - Virus-Specific Regulatory T-Cell Dysregulation in Post-COVID-19 and EBV-Associated Vasculitis
D2.430 - Automated 24-Hour Quantification of Scratching Behavior Reveals Distinct Physiological and Allergic Pruritus Signatures in Mice
D2.433 - Clinical and Oxidative Function Profiles in Heterozygous Female Carriers of X-Linked Chronic Granulomatous Disease
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.457 - Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome
D2.460 - Does Aspirin change outcomes of dupilumab therapy?
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download